Innovations driving biomarker evaluation and use
Beyond biomarkers: an opportunity to address the ‘pharmacodynamic gap’ in pediatric drug development
Translational medicine: path to personalized and public health
Backtracking on CYP2C19 genotyping in clopidogrel therapy?
Melanoma-targeted therapy based on V600E BRAF mutation
Tumor-specific therapy based on BRCA1/2 mutation status
Trastuzumab for HER2-positive gastric and gastroesophageal junction cancers
Book Review: Biomarkers in drug development: a handbook of practice, application and strategy
Restructuring proteomics through verification
Emergence of biomarkers in nephropharmacology
Applications of ‘decisionable’ biomarkers in cardiovascular drug development
Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers?
Using biomarkers to detect oral cancer holds potential for saving lives when the cancer is most curable
Predicting which lung cancer patients can benefit from tivozanib
Study suggests umbilical cord blood is no longer suitable for assessing allergy risk in newborns
Biomarker may be used to develop potential screening test for early-stage lung cancer
Biomarker discovery brings us one step closer to personalized cancer treatment
Gender-specific differences in the urinary expression of aldosterone, IL-1α and IL-1β
Biomarker tests for fetal lung maturity
Mass spectrometry-coupled techniques for viral-related disease biomarker identification
Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function
A window into your heart: taking cardiac troponin to the next level
Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicine
Differential proteomics of sperm: insights, challenges and future prospects
Acknowledgements